Structure-based identification of small molecule binding sites using a free energy model.
We separately have shown that the maximal druglike affinity of a given binding site on a protein can be calculated on the basis of the binding-site structure alone by using a desolvation-based free energy model along with the notion that druglike ligands fall into certain physiochemical property ranges. Here, we present an approach where we reformulate the calculated druggability affinity as an additive free energy to facilitate the searching of whole protein surfaces for druglike binding sites. The highest-scoring patches in many cases represent known ligand-binding sites for druggable targets, but not for difficult targets. This approach differs from other approaches in that it does not simply identify pockets with the greatest volume but instead identifies pockets that are likely to be amenable to druglike small-molecule binding. Combining the method with a functional residue prediction method called SCA (statistical coupling analysis) results in the prediction of potentially druggable allosteric binding sites on p38alpha kinase.
Coleman
Ryan G
RG
Research Technology Center, Pfizer Global Research & Development, Cambridge, Massachusetts 02139, USA.
Salzberg
Anna C
AC
Cheng
Alan C
AC
D000495:Allosteric Site; D000595:Amino Acid Sequence; D001665:Binding Sites; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D030562:Databases, Protein; D015195:Drug Design; D008024:Ligands; D048308:Mitogen-Activated Protein Kinase 14 / Q000737:chemistry; D008958:Models, Molecular; D008962:Models, Theoretical; D008969:Molecular Sequence Data; D011485:Protein Binding; D011487:Protein Conformation; D013678:Technology, Pharmaceutical / Q000379:methods*; D013816:Thermodynamics
D008024:Ligands; D048308:Mitogen-Activated Protein Kinase 14